Champions TumorGraft® Database Updated with Whole Exome Sequencing and RNA Sequencing Data
Hackensack, NJ – September 9, 2015 – Champions Oncology, Inc. (CSBR) a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that the Champions TumorGraft® database has been updated to include molecular characterization data obtained through Whole Exome Sequencing and RNA Sequencing technology. The database represents the most annotated compendium of patient-derived xenograft (PDX) models available through a web-based interface.
The Champions TumorGraft database enables access to information about more than 700 clinically-relevant PDX models. In addition to the in-depth data about cancer indication and histology, disease stage and metastatic site, patient demographics, and treatment history that was previously searchable, the data sets available for query now include single nucleotide variations (SNVs), gene insertions and deletions (InDels), gene expression levels, gene fusions and translocations, gene splice variants and copy number variations (CNVs). Users can log in to review, search and identify the best PDX models for their translational research projects.
Keren Pez, Chief Scientific Officer for Champions Oncology, explained, “Through extensive analysis, we have one of the most highly-characterized platforms available. Making the rich data sets directly available to the translational research community means that infinitely more detailed information around PDX models most suitable for a wide range of research initiatives in the oncology drug development process is readily accessible. This can significantly advance project-planning steps and accelerate timelines. Data can be delivered in multiple formats, from summary to raw data, depending on user needs and preferences. Our scientific team is committed to continue the development of this platform and its comprehensive database.”